Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition
Friday, December 26, 2025, 11:17 a.m. ET in New York. In that context—a quiet, low‑liquidity post‑Christmas session with major U.S. indexes hovering near record highs—Vera Therapeutics, Inc. (Nasdaq: VERA) is trading lower midday. Reuters and the AP both describe today’s market as subdued, with institutions largely “checked out” for year‑end and the broader tape moving only slightly. Reuters As of the latest available quote in this session, VERA is at about $54.24, down ~2.6% on the day, with a day range roughly $54.05–$55.30 and notably light volume—exactly the kind of trading environment where single‑stock moves can look louder than the